Skip to content
RDL
Network
Ecosystem
Switch app
TR
About
FAQ
Sign in
Get started
Biologic agents in rheumatology: unmet issues after 200 trials and $200 billion sales — John P A Ioannidis (2013) | RDL Network
Back
Cite
Save
Save for later
Share
Home
Publications
Biologic agents in rheumatology: unmet issues after 200 trials and $200 billion sales
Shared by
John P A Ioannidis
Stanford University
Biologic agents in rheumatology: unmet issues after 200 trials and $200 billion sales
Article
2013
en
Authors
+2 more
John P A Ioannidis
Stanford University
FK
Fotini B. Karassa
ED
Eric Druyts
Discussion
(0)
Sign in
to like and join the discussion.
No comments yet. Be the first to comment.
Related publications
Article
2015
Survey of Agricultural Machinery Service Quality after Sales in Liaoning
Zhi Li
Article
2001
Bias in uncontrolled therapeutic trials in rheumatology due to selection of populations with extreme characteristics.
John P A Ioannidis
,
Fotini B. Karassa
Article
2005
Clinical trials in multiple sclerosis: methodological issues
Giancarlo Comi
,
Massimo Filippi
Article
1999
Issues in Comparisons Between Meta-analyses and Large Trials
John P A Ioannidis
,
Joseph C. Cappelleri
,
Joseph Lau
Article
1998
Issues in Comparisons Between Meta-analyses and Large Trials
John P A Ioannidis
Discussion(0)
No comments yet. Be the first to comment.